I'm reluctant to stay in this rabbit hole, but at the same time if you have a significant investment, I certainly won't fault you for asking questions. The answer to your question is in the timing.
The company gave the signal that they were in control of when to list, shortly before Christmas. The impending holiday season, and their communications referring to moving ahead in January, leads me to believe they intended to start the road show in January, at the end of which they would be clear to fill the IPO books, and then list. NASDAQ biotech stocks took a big hit starting on January 3rd, precisely during the period they would have started running the roadshow. Look at the charts. The only way you can continue to believe they would have simply gone ahead because all hurdles were cleared, is if you ignore that exact adverse market conditions the BOD explained caused them to pivot.
So my question remains the same: why specifically would you ignore that? I'm sincerely interested because I like to look at all angles.
IHL Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
